The efficacy of PD-L1 blockade on PD-L1 negative medulloblastoma is dependent on timing and the tumor microenvironment

被引：0
|
作者：
Allen, Frederick [1 ,2 ]
Dorand, Rodney Dixon [1 ]
Rauhe, Peter [1 ,2 ]
Petrosiute, Agne [1 ,2 ,3 ]
Huang, Alex Y. [2 ,4 ,5 ]
机构：
[1] Case Western Reserve Univ, Cleveland, OH 44106 USA
[2] Univ Hosp, Dept Pediat, Cleveland, OH USA
[3] Rainbow Babies & Childrens Hosp, Univ Hosp, 2101 Adelbert Rd, Cleveland, OH 44106 USA
[4] Angie Fowler AYA Canc Inst, Cleveland, OH USA
[5] Case Comprehens Canc, Cleveland, OH USA
来源：
JOURNAL OF IMMUNOLOGY | 2018年 / 200卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
178.14
引用
收藏
页数：3
相关论文
共 50 条
  • [21] Cordycepin enhances the Anticancer efficacy of PD-L1 blockade by modulating the tumor microenvironment of colon cancer
    Feng, Chen
    Chen, Rongzhang
    Gao, Xinran
    Fang, Weiwei
    Wu, Shaoxian
    Chen, Lujun
    Zheng, Xiao
    Ji, Xinyue
    Yuan, Maoling
    Fu, Yuanyuan
    Ying, Hanjie
    Shen, Tao
    Zhu, Dawei
    Jiang, Jingting
    EUROPEAN JOURNAL OF PHARMACOLOGY, 2024, 985
  • [22] Beyond PD-L1: unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumour microenvironment
    Miles, J.
    Gumuzio, J.
    Calleja, V.
    EUROPEAN JOURNAL OF CANCER, 2024, 211 : S99 - S100
  • [23] Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
    Iwai, Y
    Ishida, M
    Tanaka, Y
    Okazaki, T
    Honjo, T
    Minato, N
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (19) : 12293 - 12297
  • [24] The PD-1: PD-L1 pathway in the context of the osteosarcoma tumor microenvironment
    Koirala, Pratistha
    Gill, Jonathan
    Roth, Michael
    Piperdi, Sajida
    Park, Amy
    Poon, Vincent
    Fremed, Michael
    Hoang, Bang
    Gorlick, Richard
    CANCER RESEARCH, 2015, 75
  • [25] Efficacy of PD-1/PD-L1 blockade monotherapy in clinical trials
    Zhao, Bin
    Zhao, Hong
    Zhao, Jiaxin
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2020, 12
  • [26] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    LABORATORY INVESTIGATION, 2015, 95 : 123A - 123A
  • [27] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    MODERN PATHOLOGY, 2015, 28 : 123A - 123A
  • [28] PD-L1 copy number gains: a predictive biomarker for PD-1/PD-L1 blockade therapy?
    Inoue, Yusuke
    Osman, Murat
    Suda, Takafumi
    Sugimura, Haruhiko
    TRANSLATIONAL CANCER RESEARCH, 2016, 5 : S199 - S202
  • [29] PD-L1 expression in equine malignant melanoma and functional effects of PD-L1 blockade
    Ganbaatar, Otgontuya
    Konnai, Satoru
    Okagawa, Tomohiro
    Nojima, Yutaro
    Maekawa, Naoya
    Minato, Erina
    Kobayashi, Atsushi
    Ando, Ryo
    Sasaki, Nobuya
    Miyakoshi, Daisuke
    Ichii, Osamu
    Kato, Yukinari
    Suzuki, Yasuhiko
    Murata, Shiro
    Ohashi, Kazuhiko
    PLOS ONE, 2020, 15 (11):
  • [30] PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy
    Bocanegra, Ana
    Blanco, Ester
    Fernandez-Hinojal, Gonzalo
    Arasanz, Hugo
    Chocarro, Luisa
    Zuazo, Miren
    Morente, Pilar
    Vera, Ruth
    Escors, David
    Kochan, Grazyna
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (16) : 1 - 17
12345